Zai Lab is a patient-focused, innovative, commercial-stage, global biopharmaceutical company based in China and the U.S. We are focused on bringing best-in-class and first-in-class medicines for oncology, autoimmune disorders, infectious diseases and neurological disorders to patients in greater China and around the world.
Zai Lab is a fully integrated biopharmaceutical company with end-to-end capabilities. Zai has internal R&D centers to advance its discovery pipeline, a strong clinical development team that currently manages more than 50 ongoing or planned clinical trials, small-molecule and large-molecule manufacturing facilities, an experienced regulatory affairs group, and a highly specialized commercial team to support marketing of innovative products.
Zai Lab has significantly expanded its global presence in recent years. The company now has its headquarters and an R&D center in Shanghai, clinical and regulatory offices in Beijing, manufacturing and R&D facilities in Suzhou, commercial offices in Hong Kong, Taiwan and Guangzhou, and U.S. offices in Menlo Park and Cambridge. As of December 2021, the Company had a global team of more than 1,900 employees.